Literature DB >> 15298622

Helicobacter pylori eradication treatment modulates epithelial cell proliferation and tissue content of hepatocyte growth factor in the gastric mucosa.

M Suzuki1, H Suzuki, T Masaoka, S Tanaka, K Suzuki, H Ishii.   

Abstract

BACKGROUND: Although Helicobacter pylori infection is now acknowledged as a major promoter of gastric cancer in humans, the carcinogenetic process of this effect has not been fully elucidated. Precancerous lesions such as intestinal metaplasia, enhanced proliferation of epithelial cells and elevated level of growth factors have been postulated to play a role. AIM: To analyse a relationship between gastric mucosal proliferation, mucosal content of hepatocyte growth factor and prevalence of intestinal metaplasia before and after successful H. pylori eradication therapy.
METHODS: We evaluated 25 H. pylori-eradicated patients. At initial endoscopic examination, two biopsy tissue samples each were obtained from the antrum and great curvature of the corpus. Tissue content of hepatocyte growth factor and neutrophil myeloperoxidase were measured using an ELISA method, and histological assessment of intestinal metaplasia (haematoxylin and eosin) and proliferating cells (Ki-67 immunostaining) was performed. The patients were treated with a 1-week course of triple therapy. At 10 months after successful eradication, biochemical and histological assessments were repeated.
RESULTS: Among all patients (n = 25), no intestinal metaplasia was detected in the corpus mucosa, but was observed in 10 patients (40%) in the antrum. This prevalence ratio was not changed after eradication. A slight decrease in HGF content was demonstrated in both sites, but the level of antral hepatocyte growth factor was significantly decreased in patients with intestinal metaplasia but not in those without. Proliferative index (Ki-67 positive cells/epithelium) was decreased after eradication therapy in both sites. An increase in proliferative index was observed in the antrum with intestinal metaplasia compared with that without, which significantly decreased after eradication therapy.
CONCLUSIONS: H. pylori eradication therapy in the present study afforded an inhibitory effect on epithelial cell proliferation and on the mucosal content of HGF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15298622     DOI: 10.1111/j.1365-2036.2004.01971.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  5 in total

Review 1.  Latest insights into the effects of Helicobacter pylori infection on gastric carcinogenesis.

Authors:  Kazunari Murakami; Masaaki Kodama; Toshio Fujioka
Journal:  World J Gastroenterol       Date:  2006-05-07       Impact factor: 5.742

Review 2.  Causal role of Helicobacter pylori infection and eradication therapy in gastric carcinogenesis.

Authors:  Masanori Ito; Shinji Tanaka; Tomoari Kamada; Ken Haruma; Kazuaki Chayama
Journal:  World J Gastroenterol       Date:  2006-01-07       Impact factor: 5.742

Review 3.  Clinical prevention of gastric cancer by Helicobacter pylori eradication therapy: a systematic review.

Authors:  Masanori Ito; Shunsuke Takata; Masana Tatsugami; Yoshihiro Wada; Shinobu Imagawa; Yoshiaki Matsumoto; Akemi Takamura; Shosuke Kitamura; Taiji Matsuo; Shinji Tanaka; Ken Haruma; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2009-04-01       Impact factor: 7.527

4.  MET4 expression predicts poor prognosis of gastric cancers with Helicobacter pylori infection.

Authors:  Naoko Sakamoto; Hironori Tsujimoto; Risa Takahata; Brian Cao; Ping Zhao; Nozomi Ito; Hideyuki Shimazaki; Takashi Ichikura; Kazuo Hase; George F Vande Woude; Nariyoshi Shinomiya
Journal:  Cancer Sci       Date:  2017-03       Impact factor: 6.716

Review 5.  Human Gut Microbiota: Toward an Ecology of Disease.

Authors:  Susannah Selber-Hnatiw; Belise Rukundo; Masoumeh Ahmadi; Hayfa Akoubi; Hend Al-Bizri; Adelekan F Aliu; Tanyi U Ambeaghen; Lilit Avetisyan; Irmak Bahar; Alexandra Baird; Fatema Begum; Hélène Ben Soussan; Virginie Blondeau-Éthier; Roxane Bordaries; Helene Bramwell; Alicia Briggs; Richard Bui; Matthew Carnevale; Marisa Chancharoen; Talia Chevassus; Jin H Choi; Karyne Coulombe; Florence Couvrette; Samantha D'Abreau; Meghan Davies; Marie-Pier Desbiens; Tamara Di Maulo; Sean-Anthony Di Paolo; Sabrina Do Ponte; Priscyla Dos Santos Ribeiro; Laure-Anne Dubuc-Kanary; Paola K Duncan; Frédérique Dupuis; Sara El-Nounou; Christina N Eyangos; Natasha K Ferguson; Nancy R Flores-Chinchilla; Tanya Fotakis; Mariam Gado Oumarou H D; Metodi Georgiev; Seyedehnazanin Ghiassy; Natalija Glibetic; Julien Grégoire Bouchard; Tazkia Hassan; Iman Huseen; Marlon-Francis Ibuna Quilatan; Tania Iozzo; Safina Islam; Dilan B Jaunky; Aniththa Jeyasegaram; Marc-André Johnston; Matthew R Kahler; Kiranpreet Kaler; Cedric Kamani; Hessam Karimian Rad; Elisavet Konidis; Filip Konieczny; Sandra Kurianowicz; Philippe Lamothe; Karina Legros; Sebastien Leroux; Jun Li; Monica E Lozano Rodriguez; Sean Luponio-Yoffe; Yara Maalouf; Jessica Mantha; Melissa McCormick; Pamela Mondragon; Thivaedee Narayana; Elizaveta Neretin; Thi T T Nguyen; Ian Niu; Romeo B Nkemazem; Martin O'Donovan; Matthew Oueis; Stevens Paquette; Nehal Patel; Emily Pecsi; Jackie Peters; Annie Pettorelli; Cassandra Poirier; Victoria R Pompa; Harshvardhan Rajen; Reginald-Olivier Ralph; Josué Rosales-Vasquez; Daria Rubinshtein; Surya Sakr; Mohammad S Sebai; Lisa Serravalle; Fily Sidibe; Ahnjana Sinnathurai; Dominique Soho; Adithi Sundarakrishnan; Veronika Svistkova; Tsolaye E Ugbeye; Megan S Vasconcelos; Michael Vincelli; Olga Voitovich; Pamela Vrabel; Lu Wang; Maryse Wasfi; Cong Y Zha; Chiara Gamberi
Journal:  Front Microbiol       Date:  2017-07-17       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.